The prognostic effects of the transcription factor FOSB expression in NSCLC are dependent on the mutation status of the TP53 gene: its expression indicates a positive prognosis in NSCLC patients harboring wild-type TP53 while a negative one in those harboring mutant TP53. Accordingly, FOSB expression holds promise as a novel prognostic biomarker for NSCLC in combination with a specific genetic background of TP53. Here, FOSB is linked to non-small cell lung carcinoma.